CORPORATE OVERVIEW
Spyre is focused on developing next generation therapeutics for people living with IBD, including ulcerative colitis (UC) and Crohn’s disease (CD).
Our portfolio of novel and proprietary monoclonal antibody product candidates has the potential to address unmet needs in IBD care and, if approved, we believe our pipeline candidates may provide promising treatment options to help patients living with IBD.
DISEASE FOCUS / MARKET OPPORTUNITY
IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders: UC and CD.
IBD affects millions of individuals worldwide. In the United States, it is estimated that approximately 2.4 million individuals are currently diagnosed with IBD.
A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics. Treatment plans are often tailored to the individual’s disease severity, location, and response to therapy. In some cases, surgical interventions such as bowel resection or ostomy formation may be necessary.
There remain substantial unmet needs in IBD management, including:
Our portfolio of potentially best-in-class antibodies was discovered and developed by our partner, Paragon Therapeutics. Spyre is the second company that was founded upon technology spun out of Paragon, a group of leading entrepreneurial scientists and investors with extensive monoclonal antibody experience.